News|Articles|November 4, 2013

WuXi Manufacturing Facility Passes FDA Inspection

Author(s)Pharmaceutical Technology Editors

WuXi PharmaTech completed a general GMP and pre-approval inspection from FDA.

The CRO/CMO WuXi PharmaTech, reports that its that its small-molecule API and advanced intermediate manufacturing facility of WuXi’s wholly owned subsidiary Shanghai SynTheAll Pharmaceutical (STA) completed a general GMP and pre-approval inspection from FDA with no Form 483 issued.

Source: WuXi PharmaTech

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

WuXi Manufacturing Facility Passes FDA Inspection

Related Content

GSK Cambridge Move Signals Shift in Drug Scale-Up Strategy

FDA's Manufacturing Registration Rule's Impact on Advanced Therapies: Part 1

Technology Transfer Between Contractors, A Panel Discussion, Part 2

Midyear 2026 Industry Report: Taking Stock of Pharma Manufacturing, AI, and Regulatory Trends

European Biotechs Reshaping Respiratory Disease

Trending on Pharmaceutical Technology

European Biotechs Reshaping Respiratory Disease

GSK Cambridge Move Signals Shift in Drug Scale-Up Strategy

Midyear 2026 Industry Report: Taking Stock of Pharma Manufacturing, AI, and Regulatory Trends

Six Months In: A 2026 Progress Check on Pharma Manufacturing, AI, and Regulatory Shifts

FDA's Manufacturing Registration Rule's Impact on Advanced Therapies: Part 1